INS and Hypoglycemia: The results from the current study support these Phase 2 trial findings and can be further extended to suggest that, even in situations when there is a substantial mismatch between the insulin dose administered and the amount of insulin required, once-weekly icodec is not associated with an increased risk of hypoglycaemia compared with once-daily glargine U100.